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Summary
Background Alzheimer’s disease and its complications are the leading cause of death in adults with Down syndrome. 
Studies have assessed Alzheimer’s disease in individuals with Down syndrome, but the natural history of biomarker 
changes in Down syndrome has not been established. We characterised the order and timing of changes in biomarkers 
of Alzheimer’s disease in a population of adults with Down syndrome.
Methods We did a dual-centre cross-sectional study of adults with Down syndrome recruited through a population-
based health plan in Barcelona (Spain) and through services for people with intellectual disabilities in Cambridge 
(UK). Cognitive impairment in participants with Down syndrome was classified with the Cambridge Cognitive 
Examination for Older Adults with Down Syndrome (CAMCOG-DS). Only participants with mild or moderate 
disability were included who had at least one of the following Alzheimer’s disease measures: apolipoprotein E allele 
carrier status; plasma concentrations of amyloid β peptides 1–42 and 1–40 and their ratio (Aβ1–42/1–40), total tau protein, 
and neurofilament light chain (NFL); tau phosphorylated at threonine 181 (p-tau), and NFL in cerebrospinal fluid 
(CSF); and one or more of PET with ¹⁸F-fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy 
euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative 
on Neurodegeneration. We used a first-order locally estimated scatterplot smoothing curve to determine the order 
and age at onset of the biomarker changes, and the lowest ages at the divergence with 95% CIs are also reported 
where appropriate.
Findings Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), 
we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer’s 
disease, and 83 [21%] with Alzheimer’s disease dementia) and 242 euploid controls. CSF Aβ1–42/1–40 and plasma NFL 
values changed in individuals with Down syndrome as early as the third decade of life, and amyloid PET uptake 
changed in the fourth decade. ¹⁸F-fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth 
decade of life, followed by hippocampal atrophy and changes in cognition in the fifth decade of life. Prodromal 
Alzheimer’s disease was diagnosed at a median age of 50·2 years (IQR 47·5–54·1), and Alzheimer’s disease 
dementia at 53·7 years (49·5–57·2). Symptomatic Alzheimer’s disease prevalence increased with age in individuals 
with Down syndrome, reaching 90–100% in the seventh decade of life.
Interpretation Alzheimer’s disease in individuals with Down syndrome has a long preclinical phase in which 
biomarkers follow a predictable order of changes over more than two decades. The similarities with sporadic and 
autosomal dominant Alzheimer’s disease and the prevalence of Down syndrome make this population a suitable 
target for Alzheimer’s disease preventive treatments.
Funding Instituto de Salud Carlos III, Fundació Bancaria La Caixa, Fundació La Marató de TV3, Medical Research 
Council, and National Institutes of Health.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Down syndrome (also referred to as trisomy 21) is the 
most frequent form of genetic developmental and 
intellectual disability, affecting 5·8 million people 
worldwide.1 Life expectancy for people with Down 
syndrome has greatly increased because of improved 
medical care, exceeding 60 years of age.2 Consequently, 
age-related comorbidities in this group have emerged, 
particularly Alzheimer’s disease. The lifetime risk of 
Alzheimer’s disease in people with Down syndrome is 
now more than 90%,3 and the disease is the leading cause 
of death in this population.4 The strong association 
between Down syndrome and Alzheimer’s disease has a 
genetic basis through a gene-dose effect of amyloid β (Aβ) 
precursor protein, which is located on chromosome 21 
and is overexpressed in people with Down syndrome.1 
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Consequently, Down syndrome is now conceptualised as 
a form of genetically determined Alzheimer’s disease, 
similar to its autosomal dominant form.5
Alzheimer’s disease pathology has been described in 
all adults with full trisomy 21 by the age of 40 years, and 
its hallmarks are qualitatively similar to those of sporadic 
Alzheimer’s disease.6 Increasing evidence from bio-
marker studies also suggest that the pathophysiology of 
the disease in Down syndrome is similar to that of the 
sporadic and autosomal dominant forms of Alzheimer’s 
disease.7,8 Several studies in individuals with Down 
syndrome have assessed Aβ brain deposition with PET 
tracers, studied plasma and cerebrospinal fluid (CSF) 
biomarkers, or described the atrophy and cerebral 
metabolic patterns of Alzheimer’s disease.9–14 Although 
longitudinal studies of Alzheimer’s disease in individuals 
with Down syndrome exist,15 the natural history of 
biomarker changes in Down syndrome has not been 
established.1,8,16–18 In this study, we assessed the order and 
timing of Alzheimer’s disease biomarker changes in a 
large cohort of adults with Down syndrome. We used 
biochemical, neuroimaging, and cognitive measures 
covering all three categories of the AT(N) biomarker 
system (assessing deposition of Aβ, hyperphosphory-
lated tau, and neurodegeneration).19 Understanding this 
pattern of changes is crucial for the design of trials in 
Down syndrome aimed at preventing or moderating the 
progression of Alzheimer’s disease.8
Methods
Study design and participants
We did a dual-centre cross-sectional study of adults with 
Down syndrome and euploid controls in Barcelona 
(Hospital of Sant Pau, Spain) and Cambridge (University 
of Cambridge, UK). Adults aged 18 years or older with 
Down syndrome in Barcelona were recruited from a 
population-based health plan designed to screen for 
Alzheimer’s disease dementia, which includes yearly 
neurological and neuropsychological assessments. Indi-
viduals in this plan interested in research studies are 
included in the Down Alzheimer Barcelona Neuroimaging 
Initiative cohort.14 In Cambridge, participants with Down 
syndrome were recruited through services for people 
with intellectual disabilities in England and Scotland, 
with the support of the UK Down Syndrome Association.12 
We included all adults with Down syndrome who had at 
least one biochemical or imaging Alzheimer’s disease 
biomarker. For euploid controls, we recruited non-
trisomic individuals aged 18 years or older up to 75 years 
from the Sant Pau Initiative on Neurodegeneration.20 
Euploid controls underwent a structured neurological 
assessment and a comprehensive battery of neuropsy-
chological tests to establish normal cognitive health. 
Inclusion criteria were normal neuropsychological results 
for their age and education level, a Clinical Dementia 
Rating Scale score of 0, and normal levels of Alzheimer’s 
disease biomarkers in CSF.20
The study was approved by the Sant Pau and the 
Cambridge Research Ethics Committees, following 
the standards for medical research in humans recom-
mended by the Declaration of Helsinki. All participants 
or their legally authorised representative gave written 
informed consent before enrolment.
Procedures
For the purpose of dementia diagnosis, we provided the 
participants’ caregivers with a semi-structured adapted 
health questionnaire, the Cambridge Examination for 
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Research in context
Evidence before this study
We searched and reviewed the literature using PubMed, 
meeting abstracts, and presentations. We searched PubMed on 
Nov 30, 2018, for research studies on established Alzheimer’s 
disease biomarkers in the plasma and cerebrospinal fluid 
(CSF; amyloid β (Aβ), tau protein, and neurofilament light 
protein [NFL]), MRI, or PET in people with Down syndrome 
using the search terms “biomarker” OR “plasma” OR “CSF” OR 
“MRI” OR “PET” AND “Down Syndrome” AND (“Alzheimer’s” or 
“dementia”). Several previous studies in Down syndrome have 
assessed Aβ brain deposition with PET tracers, studied plasma 
and CSF biomarkers, or described the atrophy and cerebral 
metabolic Alzheimer’s disease patterns. However, we found no 
previous multimodal studies assessing the natural history of 
Alzheimer’s disease in individuals with Down syndrome.
Added value of this study
To our knowledge, this is the first large multimodal biomarker 
study to characterise the natural history of Alzheimer’s disease 
in adults with Down syndrome. Biomarker changes begin more 
than two decades before Alzheimer’s disease dementia onset in 
a strikingly similar order and timing to that described in 
patients with autosomal dominant Alzheimer’s disease.
Implications of all the available evidence
Our study supports people with Down syndrome as a suitable 
population for clinical trials for Alzheimer’s disease. 
The description of the natural history of Alzheimer’s disease in 
this population would have an immediate effect on the design 
of such trials. It would also have implications in clinical practice 
because it supports the concept of Down syndrome as a form of 
genetically determined Alzheimer’s disease with a predictable 
sequence of biomarker changes.
For the Clinical Dementia 
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Mental Disorders of Older People with Down Syndrome 
and others with intellectual disabilities (CAMDEX-DS) 
developed in Cambridge, with a version adapted for the 
Spanish population. The CAMDEX-DS includes a com-
prehensive cognitive battery of neuropsychological tests, 
the Cambridge Cognitive Examination for Older Adults 
with Down Syndrome (CAMCOG-DS), that covers seven 
different cognitive domains.21 We classified participants 
with Down syndrome into asymptomatic, having prodro-
mal Alzheimer’s disease, or having Alzheimer’s disease 
dementia, in a consensus meeting between the neurol-
ogist or psychiatrist and the neuropsychologists who 
assessed the participants while masked to biomarker 
data, as previously described.14 Because of the floor effects 
of the CAMCOG-DS in adults with Down syndrome with 
severe and profound levels of intellectual disability,21 
we only included participants with mild or moderate 
intellectual disability in this analysis. We stratified the 
level of intellectual disability according to the Diagnostic 
and Statistical Manual of Mental Disorders (fifth edition)22 
as mild, moderate, or severe or profound (which were 
grouped together) on the basis of the individuals’ best-
ever level of functioning, as determined from carers’ 
reports. The information was obtained through family 
interviews and review of medical or educational records 
for past assessment results.
We screened patients for trisomy 21 using the Illumina 
Infinium Global Screening Array (Illumina, San Diego, 
CA, USA) as previously described.14 We also determined 
apolipoprotein E (APOE)-ε4 allele carrier status through 
detection of polymorphisms rs429358 and rs7412 in exon 
4 via Sanger sequencing.7,14
A subset of participants underwent a 3 Tesla MRI, a 
¹⁸F-fluorodeoxyglucose PET, amyloid PET, or a combi-
nation of these acquisitions. The amyloid tracer used was 
¹⁸F-florbetapir in Barcelona and ¹¹C-Pittsburg compound 
B in Cambridge. Structural T1 MRI was processed with 
Freesurfer (version 6)23 to extract the adjusted hippocampal 
volumes (appendix pp 3–4).24 ¹⁸F-fluorodeoxyglucose and 
¹⁸F-florbetapir PET images were co-registered to the 
individual MRI, and standardised uptake value ratios were 
extracted from the corresponding Landau regions.25,26 
Methods and findings from amyloid PET or CT scans in 
the Cambridge cohort have been published previously,12 
but data were reanalysed and converted to the Centiloid 
scale and combined with the Barcelona ¹⁸F-florbetapir data 
following standard procedures (appendix pp 5–6).27
CSF and blood samples were acquired concurrently on 
the same day. Plasma concentrations of Aβ 1–42 (Aβ1–42) 
and Aβ1–40, total tau protein, and neurofilament light chain 
(NFL) were measured using single molecule array (Simoa; 
Quanterix, Billerica, MA, USA) at Centre Hospitalier 
Universitaire Montpellier (Montpellier, France)14 or at 
Hospital of Sant Pau (Barcelona, Spain). CSF concen-
trations of Aβ1–42, Aβ1–40, tau phosphorylated at threonine 
181 (p-tau), and total tau were quantified with a com-
mercially available immunoassay in a fully auto mated 
platform (Lumipulse, Fujirebio-Europe, Ghent, Belgium).20 
CSF NFL concentrations were measured with a commer-
cial ELISA (UmanDiagnostics, Umeå, Sweden), following 
the manufacturer’s recommendations. All CSF samples 
were analysed at Hospital Sant Pau (appendix p 7). Methods 
and findings from plasma and CSF biomarkers have been 
published previously,14 but the age-related changes were 
not assessed. All participants from our paper assessing the 
diagnostic performance5 have been included in this Article. 
Notably, the methods for CSF biomarker measurement 
differs between the two studies (we used a commercially 
available ELISA in the previous study, but the Lumipulse 
fully automated platform for this study). Additionally, in 
this study, we have included 66 new plasma samples and 
47 new CSF samples from adults with Down syndrome 
and 56 new plasma samples and 160 new CSF samples 
from control participants.
Statistical analysis
We assessed differences in baseline characteristics 
between the diagnostic groups with the Kruskal-Wallis 
test and a pairwise Wilcoxon test corrected for multiple 
comparisons. To determine the order and temporality of 
the biomarker changes and cognitive decline in partic-
ipants with Down syndrome, we fitted a first-order locally 
estimated scatterplot smoothing curve for controls and 
adults with Down syndrome indepen dently.16,28 The 
model uses a standard tricubic weight function with a 
span parameter to 0·75. The exact age at which the 
intervals diverge is dependent on intrinsic limitations of 
studies assessing the natural history of biomarkers, such 
as the nature of the variable, the sensitivity of the assay, 
the slope of the association, and, in our study, the uneven 
sample sizes for the different biomarkers. Therefore, 
we defined biomarker change as the age at which the 
groups appear to start diverging visually. Nonetheless, 
we also provide the lower age at which the 95% CIs 
between groups did not overlap. When neurodevelop-
mental differences were present (different offsets such as 
hippocampal volumes in the youngest individuals) 
or when no data were available for the controls (eg, 
CAMCOG-DS scores), we visually described only the 
trajectory in adults with Down syndrome.
To compare the timing of changes in Down syndrome 
and autosomal dominant Alzheimer’s disease, we 
presented the biomarker changes both according to the 
chronological age and with respect to the median age of 
diagnosis of prodromal Alzheimer’s disease (referred in 
this study as expected symptom onset).
All statistical analyses were done with R statistical 
software. Further details for the statistical methods can 
be found in the appendix (pp 7–8).
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
For Freesurfer see https://surfer.
nmr.mgh.harvard.edu/
See Online for appendix
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the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Feb 1, 2013, and June 28, 2019 (Barcelona), and 
between June 1, 2009, and Dec 31, 2014 (Cambridge), we 
recruited participants with Down syndrome and euploid 
controls (appendix p 3). We recruited and included 
388 adults with Down syndrome (347 in Barcelona and 
41 in Cambridge) and 242 euploid controls (recruited in 
Barcelona) in our study. 174 (45%) of 388 participants 
with Down syndrome and 162 (67%) of 242 controls were 
women (table). 308 participants with Down syndrome 
were screened for trisomy 21; genetic confirmation 
of trisomy 21 was not available for 80 participants. Of 
participants with Down syndrome, 72 (19%) had mild 
intellectual disability, 175 (45%) had moderate, and 
98 (25%) had severe or profound. The number of adults 
with Down syndrome and controls was different for each 
biomarker method (appendix p 9).
We observed no clinical evidence of dementia in 
257 (66%) of the 388 participants with Down syndrome. 
Of the remaining, 48 (12%) had prodromal Alzheimer’s 
disease and 83 (21%) had Alzheimer’s disease demen-
tia. The median age of diagnosis was 50·2 years 
(IQR 47·5–54·1) for prodromal Alzheimer’s disease and 
53·7 years (49·5–57·2) for Alzheimer’s disease dementia. 
The prevalence of symptomatic Alzheimer’s disease 
(prodromal Alzheimer’s disease and Alzheimer’s disease 
dementia combined) increased exponentially from age 
40 years onwards, reaching 90–100% prevalence by the 
end of the seventh decade of life (figure 1). The evolution 
of the different bio markers along the Alzheimer’s dis-
ease continuum (asymptomatic, pro dromal Alzheimer’s 
disease, and Alzheimer’s disease dementia) is shown in 
the appen dix (p 11).
We plotted the scores on the CAMCOG scale as a 
function of age in individuals with mild and moderate 
intellectual disability separately (figure 1). Although 
neuropsychological performance cannot be directly 
compared between individuals with Down syndrome 
and controls, a visual inspection showed a decline in 
CAMCOG scores starting at about age 40 years in 
individuals with Down syndrome, particularly in partic-
ipants with moderate intellectual disability, which is 
10 years before the median age of diagnosis of prodromal 
Alzheimer’s disease (figure 1).
We compared the pattern of cortical atrophy in 
individuals with Down syndrome who had symptomatic 
Alzheimer’s disease with that in individuals who were 
asymptomatic (figure 2). Compared with participants who 










Age, years 38·7 (31·1 to 48·2) 50·2 (47·5 to 54·1) 53·7 (49·5 to 57·2) 56·6 (50·4 to 63·8) <0·0001
Sex ·· ·· ·· ·· <0·0001
Men 144 (56%) 26 (54%) 44 (53%) 80 (33%) NA
Women 113 (44%) 22 (46%) 39 (47%) 162 (67%) NA
APOE-ε4 carriers 46 (19%) 11 (23%) 15 (20%) 67 (29%) 0·10
Level of intellectual disability ·· ·· ·· ·· <0·0001
Mild 62 (27%) 6 (14%) 4 (5%) NA NA
Moderate 114 (50%) 19 (45%) 42 (56%) NA NA
Severe or profound 52 (22%) 17 (40%) 29 (38%) NA NA
CAMCOG-DS score (n=225)
Mild (n=67) 88 (82 to 91) 80 (76 to 82) 70 (66 to 75) NA <0·0001
Moderate (n=158) 75 (65 to 82) 65 (60 to 73) 41 (18 to 55) NA <0·0001
CSF Aβ1–42/1–40 (n=265) 0·078 (0·062 to 0·093) 0·042 (0·046 to 0·050) 0·046 (0·042 to 0·055) 0·106 (0·101 to 0·111) <0·0001
CSF NFL (n=230) 368·7 (233·7 to 523·1) 667·4 (484·0 to 1013·6) 1139·2 (757·3 to 1436·3) 400·0 (338·6 to 544·6) <0·0001
CSF p-tau (n=272) 30·0 (18·5 to 59·0) 110·4 (67·3 to 186·2) 155·3 (100·4 to 192·8) 32·5 (26·1 to 43·7) <0·0001
Plasma Aβ1–42 (n=435) 14·2 (12·2 to 16·4) 14·1 (11·9 to 15·8) 14·5 (12·5 to 17·0) 9·0 (7·7 to 10·1) <0·0001
Plasma NFL (n=431) 6·0 (4·6 to 10·3) 13·3 (10·7 to 18·5) 22·3 (17·2 to 30·0) 4·4 (3·3 to 6·2) <0·0001
Plasma total tau (n=427) 2·5 (2·0 to 3·1) 3·3 (2·4 to 4·0) 4·0 (2·9 to 5·0) 2·2 (1·7 to 3·4) <0·0001
Centiloid amyloid PET (n=108)* 6·4 (2·0 to 15·7) 64·7 (44·9 to 84·8) 72·6 (53·6 to 97·8) –1·9 (–10·9 to 4·4) <0·0001
FDG SUVR (n=197) 1·3 (1·3 to 1·4) 1·2 (1·1 to 1·3) 0·9 (0·8 to 1·1) 1·4 (1·3 to 1·5) <0·0001
Adjusted hippocampal volume 3 
Tesla MRI (n=330)†
–0·14 (–0·50 to 0·27) –0·87 (–1·50 to –0·59) –1·86 (–2·37 to –1·03) 0·86 (0·35 to 1·40) <0·0001
Data are n (%) or median (IQR). The n values on each row are the total number of assessments, including for both individuals with Down syndrome and controls. Percentages of APOE-ε4 carriers and level of 
intellectual disability were calculated according to the total of patients with available data in each group. CAMCOG-DS=Cambridge Cognitive Examination for Older Adults with Down Syndrome. Aβ1–40=amyloid β 
peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CSF=cerebrospinal fluid. NFL=neurofilament light chain. p-tau=tau phosphorylated at threonine 181. FDG=¹⁸F-fluorodeoxyglucose. NA=not applicable. 
SUVR=standardised uptake value ratio. *n=74 with ¹⁸F-florbetapir and n=34 with ¹¹C-Pittsburg compound B. †With MRI. 
Table: Clinical, cognitive, imaging, and biochemical markers in individuals with Down syndrome and controls
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decreased cortical thickness in the temporoparietal, 
precuneus-posterior cingulate, and frontal areas.
In the assessment of hippocampal atrophy with age, 
adults with Down syndrome had smaller hippocampi 
across the whole lifespan than did controls (figure 3G). 
A visual inspection of the data showed a steeper decline 
in hippocampal volumes at the beginning of the fifth 
decade of life in participants with Down syndrome, about 
10 years before expected symptom onset.
A comparison of the pattern of cortical hypometabolism 
in individuals who were symptomatic with those without 
symptoms showed decreased glucose metabolism in 
the temporoparietal, precuneus-posterior cingulate, and 
frontal areas in participants who were symptomatic 
(figure 2). We assessed the trajectory with age of 
the cerebral glucose metabolism as measured in the 
Landau signature, which tracks early changes in sporadic 
Alzheimer’s disease (figure 3H).26 Visually, brain meta-
bolism decreased in participants with Down syn drome 
starting from the earliest observed age. We observed a 
substantial further decrease in cerebral metabolism at 
age 37·5 years (12·7 years before expected symptom 
onset).
We compared the pattern of Aβ deposition in 
individuals who were symptomatic with that of indi-
viduals without symptoms (figure 2). Participants who 
were symptomatic showed increased global cerebral 
Aβ deposition, with a relative sparing in sensory and 
motor areas. Amyloid PET uptake started to increase in 
the latter half of the fourth decade of life, about 
12–15 years before expected symptom onset (figure 3I). 
Notably, the curves for ¹¹C-Pittsburg compound B and 
¹⁸F-florbetapir followed similar trajectories and had 
overlapping CIs in the whole age span (appendix p 6).
Conversely, CSF Aβ1–42/1–40 values decreased in individuals 
with Down syndrome starting from the earliest observed 
ages (third decade of life) and were significantly different 
from those of controls from age 28 years onwards (22 years 
before prodromal Alzheimer’s disease diagnosis),  levelling 
off in the sixth decade of life (figure 3A). CSF concentrations 
of p-tau and NFL showed similar trajectories: visually, the 
concentrations of both biomarkers started increasing in 
the fourth decade of life in individuals with Down 
syndrome (figures 3B, 3C). The CIs no longer overlapped 
for p-tau at age 39 years and for NFL at age 40 years 
(11–10 years before prodromal Alzheimer’s disease 
diagnosis). Total tau concentrations in participants with 
Down syndrome evolved similarly to p-tau (appendix p 10), 
showing differences at age 36 years.
Plasma Aβ1–42 concentrations were 58% higher in 
adults with Down syndrome than in controls across the 
whole age span (figure 3D) and did not differ between 
diagnostic groups (plasma Aβ1–42/1–40 concentrations are 
shown in the appendix [p 10]). Plasma NFL concen-
trations also increased visually from the earliest 
observed ages and were significantly different at age 
30 years (20 years before prodromal Alzheimer’s disease 
Figure 1: Clinical and neuropsychological changes with age in adults with Down syndrome
(A) Point prevalence of Alzheimer’s disease dementia, prodromal Alzheimer’s disease, and no clinical symptoms 
of Alzheimer’s disease in individuals with Down syndrome. (B) Age-related changes in CAMCOG-DS scores in 
individuals with Down syndrome with mild or moderate intellectual disability (analysed separately), with bands 
representing 95% CIs. The vertical dashed line at 50·2 years represents the median age at the expected symptom 
onset (ie, prodromal Alzheimer’s disease diagnosis). CAMCOG-DS=Cambridge Cognitive Examination for Older 




















18 20 25 30 35 40 45 50 55 60 65 70



























Figure 2: Imaging signature of Alzheimer’s disease in adults with Down syndrome for brain structure, 
glucose metabolism, and amyloid β deposition
All panels compare individuals with Down syndrome with symptomatic Alzheimer’s disease with those with 
no clinical evidence of dementia. The left panel represents loss of cortical thickness, the middle panel loss of brain 
glucose metabolism, and the right panel the increase in cerebral fibrillar amyloid β deposition.
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p value p value p value
10–2 10–12 10–2 10–10 10–2 10–8
Articles
www.thelancet.com   Vol 395   June 27, 2020 1993
Figure 3: Biomarker changes with age in adults with Down syndrome and control participants
Shading represents 95% CIs. The vertical dashed lines at 50·2 years represent the age at the expected symptom onset (eg, median age of prodromal Alzheimer’s disease diagnosis). Aβ1–40=amyloid 
β peptide 1–40. Aβ1–42=amyloid β peptide 1–42. CSF=cerebrospinal fluid. FDG=¹⁸F-fluorodeoxyglucose. NFL=neurofilament light chain. SUVR=standardised uptake value ratio. 
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diagnosis; figure 3F). Plasma tau concentrations in 
participants with Down syndrome and controls over-
lapped widely (figure 3E). The group comparisons 
for all the biomarkers along the Alzheimer’s disease 
continuum (asymptomatic vs prodromal Alz heimer’s 
disease vs Alzheimer’s disease dementia) are shown in 
the appendix (p 11).
The changes in cognitive, biochemical, and imaging 
biomarkers in individuals with Down syndrome 
expanded for more than 20 years (figure 4). At age 
30 years, the early decrease in CSF Aβ1–42/1–40 values was 
accompanied by increases in plasma NFL concentrations, 
increases in CSF p-tau concentrations, and reductions in 
brain metabolism. At age 40 years, changes in Centiloid 
Aβ scale scores and brain atrophy occurred together 
with cognitive impairment, followed by prodromal 
Alzheimer’s disease and Alzheimer’s disease dementia 
at the beginning of the fifth decade of life in these 
individuals.
Discussion
To our knowledge, this was the first large multimodal 
biomarker study to characterise the natural history of 
Alzheimer’s disease in adults with Down syndrome. We 
found sequential changes in biomarkers over decades, as 
well as progressive cognitive impairment. In accordance 
with the conceptualisation of Down syndrome as a form 
of genetically determined Alzheimer’s disease,5 these 
changes began more than two decades before the onset of 
Alzheimer’s disease dementia, in a strikingly similar 
order and timing to that described in autosomal dominant 
Alzheimer’s disease.16,18
Symptomatic Alzheimer’s disease prevalence in indi-
viduals with Down syndrome increased exponentially 
with age in our study, reaching 90–100% in the seventh 
decade of life. The median age of diagnosis of prodromal 
Alzheimer’s disease and clinical Alzheimer’s disease 
dementia in our study are in agreement with a large 
study that used clinical records in the UK (mean age at 
dementia onset of 55·8 years, SD 6·3).29 The variability 
in dementia onset in both ours and the UK-only study 
was less than that reported in the Colombian Kindred 
study (mean age 38·5 years, SD 8·6), and similar to 
those reported for the other mutations in autoso -
mal dominant Alzheimer’s disease.30 The prevalence 
estimates for Alzheimer’s disease dementia in cross-
sectional and longitudinal studies show substantial 
variability.1,3 Our study is among those with the highest 
estimates, probably because of our research protocol 
with comprehensive neuropsychological and neurological 
assessments, which allowed us to detect individuals with 
prodromal Alzheimer’s disease.
Early clinicopathological studies and recent biomarker 
studies have shown that Alzheimer’s disease pathology 
and CSF and plasma biomarker changes in individuals 
with Down syndrome are qualitatively the same as 
in sporadic Alzheimer’s disease.6,14 On one hand, the 
patterns of cerebral Aβ deposition, atrophy, and hypo-
metabolism in our study are similar to those found in 
previous reports, indicating that Alzheimer’s disease in 
individuals with Down syndrome targets the same 
cortical regions affected in the sporadic and autosomal 
dominant forms.9 On the other hand, cognitive perfor-
mance and other biomarkers, such as plasma Aβ1–42 
concentrations or hippocampal volumes, had clear 
different starting points in the youngest individuals 
(and throughout all ages). These abnormalities, which 
have been consistently reported in the literature,9,31 
underscore the importance of considering the neuro-
developmental differences in individuals with Down 
syndrome and the level of baseline intellectual disability 
when interpreting cognitive and biomarker results.
In our study, the CSF Aβ1–42/1–40 ratios and plasma NFL 
concentrations were the first biomarkers to change 
by age 28–30 years, more than 20 years before prodro-
mal Alzheimer’s disease diagnosis. Fibrillar amyloid 
deposition was not detectable with PET until almost 
10 years after the Aβ1–42/1–40 and NFL changes. This onset 
is similar to those reported in DIAN16 or in the Colombian 
E280A PSEN1 kindred18 studies and is in agreement with 
evidence showing the reduced sensitivity of amyloid 
PET in the earliest stages of amyloid deposition in 
individuals with Down syndrome.32 Additionally, the 
change in CSF Aβ1–42 concentrations might occur earlier 
than reported in this study because, at younger ages, 
both children with Down syndrome33 and children with 
Figure 4: Integrated model of the natural history of Alzheimer’s disease in 
individuals with Down syndrome
Comparison of structural, metabolic, and biochemical biomarker changes as 
a function of age by use of the standardised differences between participants 
with Down syndrome and controls fitted with a locally estimated scatterplot 
smoothing curve. Positive standardised differences represent higher biomarker 
values in participants with Down syndrome than in euploid controls, and 
negative values represent lower biomarker values. The vertical dashed line at 
50·2 years represents the age at the expected symptom onset (median age 
of prodromal Alzheimer’s disease diagnosis). Aβ1–40=amyloid β peptide 1–40. 
Aβ1–42=amyloid β peptide 1–42. CAMCOG-DS=Cambridge Cognitive 
Examination for Older Adults with Down Syndrome. CSF=cerebrospinal fluid. 
NFL=neurofilament light chain. p-tau=tau phosphorylated at threonine 181.
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a presenilin-1 mutation16,34 have shown higher CSF 
Aβ1–42 concentrations than those of age-matched controls. 
Changes in brain metabolism in individuals with Down 
syndrome was the biomarker that followed a more 
linear decrease, compared with that of other biomarkers, 
and we observed significant differences at about age 
37·5 years, nearly 13 years before prodromal Alzheimer’s 
disease diagnosis. CSF p-tau and NFL concentrations 
began to increase at about age 40 years, 10 years before 
prodromal Alzheimer’s disease diagnosis, similar to 
autosomal dominant Alzheimer’s disease.16 Hippo-
campal atrophy was evident from an early age, probably 
reflecting neurodevelopmental differences. Nonetheless, 
hippocampal volumes decreased faster at about age 
40 years, 10 years before prodromal Alzheimer’s disease 
diagnosis, in parallel with a decline in CAMCOG-DS 
scores. Dementia diagnosis occurred approximately 
3 years after prodromal Alzheimer’s disease diagnosis. 
This sequence of changes, summarised in the combined 
model (figure 4), is again strikingly similar to that 
described in autosomal dominant Alzheimer’s disease.16
The main strengths of this study are the large 
population size, with a wide age range, and the 
comprehensive and multimodal nature of the assess-
ment. The main lim itations are its cross-sectional 
design and the differences in sample sizes for the 
different biomarker tests. The unequal sample size of 
each biomarker affects the CI calculations and the exact 
estimates of the ages for the biomarker changes. For 
this reason, and because of the intrinsic limitations of 
studies assessing the natural history of biomarkers 
(eg, different nature of the variables with different 
slopes and different sensitivities of the assays), we used 
a descriptive analysis, which we complemented with the 
mathematical approach previously used in studies of 
autosomal dominant Alzheimer’s disease.16 This limi-
tation is clearly exemplified by the differences between 
the estimates for plasma and CSF NFL concentrations. 
The neurodevelopmental and biological differences as-
sociated with Down syndrome also complicate the 
deter mination of the estimates, as exemplified in the 
cog nitive performance assessment and in other bio-
markers, such as hippocampal volumes or plasma Aβ1–42 
concentrations. Finally, as in previous studies in 
individuals with Down syndrome,29 we used age at 
diagnosis as proxy of age of onset, but we acknowledge 
that this approach might have underestimated age of 
onset.
Our results have several important implications. First, 
they support the concept of Down syndrome as a form 
of genetically determined Alzheimer’s disease,5 which 
has been shown to have a profound effect in patient 
management and family counselling for autosomal 
dominant Alzheimer disease. Second, neurodegenera-
tive changes, as measured by plasma NFL increases or 
brain hypometabolism, might occur much earlier than 
previously thought in individuals with Down syndrome, 
even before fibrillar Aβ deposition is detectable by PET. 
These results reinforce the adequacy of the unbiased 
descriptive classification scheme for Alzheimer’s disease 
biomarkers of the AT(N) system.19 Third, our results 
showed that the biochemical changes in their direction 
and magnitude are similar to those described in sporadic 
and autosomal dominant Alzheimer’s disease. The 
atrophy, hypometabolic, and Aβ deposition maps were 
also similar to those described in the sporadic and 
autosomal dominant forms of the disease. Finally, 
our finding of a long preclinical phase supports the 
consideration of people with Down syndrome as a 
suitable population for clinical trials of Alzheimer’s 
disease.
Regrettably, individuals with Down syndrome have yet 
to be included in preventive clinical trials. Such trials 
would, admittedly, pose additional challenges compared 
with those done in the general population regarding 
informed consent and concerns about the feasibility of 
completing all assessments. However, our study shows 
that a substan tial proportion of adults with Down 
syndrome are capable and willing to do all the 
multimodal studies required in a trial. Clinical trials in 
this population have obvious advantages: the ultra-high 
risk for developing symptomatic Alzheimer’s disease 
and, as we showed here, a predictable sequence of events 
make this population ideal for preventive trials in 
Alzheimer’s disease, together with individuals with its 
autosomal dominant form. Notably, Down syndrome 
is much more common than autosomal dominant 
Alzheimer’s disease. Given the similarities between 
both sporadic and autosomal dominant Alz heimer’s 
disease and Alzheimer’s disease in individuals with 
Down syndrome, such therapies could prove ben eficial 
for all of these groups.35 Future studies should assess 
the effects of potential genetic modifiers (including the 
APOE haplotype and polygenic risk factors), the potential 
differences between individuals with full trisomy 21 
and those with partial translocations or mosaicism and, 
importantly, the relationships between biomarkers. The 
different biomarkers do indeed show correlations, and 
multimodal studies are certainly needed to assess the 
effect of pathophysiological biomarkers on topographical 
biomarkers.5 Additional studies specifically investigating 
cognition are also needed to assess whether the differ-
ences in the CAMCOG-DS rate of decline in individuals 
with mild versus moderate intellectual disability are due 
to insufficient test sensitivity for highly functioning 
individuals, differences in underlying biology supportive 
of the cognitive reserve hypothesis, or the population 
composition in our study.
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